Spyre Therapeutics (SYRE) News Today $12.79 -1.20 (-8.58%) Closing price 04:00 PM EasternExtended Trading$12.75 -0.04 (-0.31%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Spyre Therapeutics Announces Grants of Inducement AwardsApril 4 at 4:05 PM | prnewswire.comPictet Asset Management Holding SA Buys 266,418 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Pictet Asset Management Holding SA lifted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 32.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,092,124 shares of the company'April 2 at 4:30 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Time to Sell?Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Should You Sell?April 2 at 4:11 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 7.7% - Here's What HappenedSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 7.7% - What's Next?April 1 at 3:31 PM | marketbeat.comSwiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Swiss National Bank grew its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 38.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 68,600 shares of the company's stock after purchasing an additional 19,000 sharesMarch 30, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's What HappenedMarch 29, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 28, 2025 | finanznachrichten.deSpyre Therapeutics (NASDAQ:SYRE) Shares Up 5.2% - Still a Buy?Spyre Therapeutics (NASDAQ:SYRE) Shares Up 5.2% - Here's WhyMarch 28, 2025 | marketbeat.comNatixis Advisors LLC Purchases Shares of 17,300 Spyre Therapeutics, Inc. (NASDAQ:SYRE)Natixis Advisors LLC purchased a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,300 shares of the company's stock, vMarch 28, 2025 | marketbeat.comAptorum Group (NASDAQ:APM) vs. Spyre Therapeutics (NASDAQ:SYRE) Head to Head SurveyMarch 28, 2025 | americanbankingnews.comSpyre Therapeutics says first patient dosed in Phase 1 trial of SPY003March 27, 2025 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year Low - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week Low - Should You Sell?March 27, 2025 | marketbeat.comSpyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyMarch 27, 2025 | prnewswire.comEFG Asset Management North America Corp. Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)EFG Asset Management North America Corp. raised its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 58.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,818 shares of the compMarch 27, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6.4% - Here's What HappenedSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 6.4% - What's Next?March 26, 2025 | marketbeat.comEmerald Advisers LLC Acquires 254,222 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Emerald Advisers LLC grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 86.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 546,791 shares of the company's stock after purchasing an aMarch 24, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Charles Schwab Investment Management Inc. boosted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 379,650 sharMarch 23, 2025 | marketbeat.comCommit To Buy Spyre Therapeutics At $12.50, Earn 13.5% Annualized Using OptionsMarch 21, 2025 | nasdaq.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Here's WhyMarch 19, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Coverage Initiated at Wolfe ResearchWolfe Research initiated coverage on Spyre Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $27.00 target price for the company.March 19, 2025 | marketbeat.comSpyre Therapeutics initiated with an Outperform at Wolfe ResearchMarch 18, 2025 | markets.businessinsider.comVictory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Victory Capital Management Inc. bought a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 268,076 shares of the company's stock, valued at approximatelyMarch 15, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by BrokeragesShares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned a consensus recommendation of "Buy" from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy ratingMarch 14, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - Should You Buy?Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up - What's Next?March 12, 2025 | marketbeat.comCandriam S.C.A. Has $5.76 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Candriam S.C.A. boosted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 135.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,591 shares of the company's stock after buyingMarch 9, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsMarch 7, 2025 | prnewswire.comJonesTrading Sticks to Its Hold Rating for Spyre Therapeutics (SYRE)March 3, 2025 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)March 1, 2025 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Shares Up 6.6% After Earnings BeatSpyre Therapeutics (NASDAQ:SYRE) Trading Up 6.6% Following Earnings BeatMarch 1, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPSSpyre Therapeutics (NASDAQ:SYRE - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.08.February 28, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateFebruary 28, 2025 | finanznachrichten.deSpyre Therapeutics files $500M mixed securities shelfFebruary 28, 2025 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Spyre Therapeutics (SYRE)February 28, 2025 | markets.businessinsider.comSpyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | prnewswire.comSpyre Therapeutics (SYRE) Projected to Post Earnings on ThursdaySpyre Therapeutics (NASDAQ:SYRE) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year Low - Should You Sell?Spyre Therapeutics (NASDAQ:SYRE) Hits New 12-Month Low - Here's What HappenedFebruary 25, 2025 | marketbeat.comSpyre Therapeutics to Participate in Upcoming March Investor ConferencesFebruary 25, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 6.7% - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Trading Down 6.7% - Should You Sell?February 22, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Upgraded to "Strong-Buy" at The Goldman Sachs GroupThe Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday.February 21, 2025 | marketbeat.comSpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis OrganisationFebruary 19, 2025 | prnewswire.comSpyre Therapeutics initiated with early-stage designation at Goldman SachsFebruary 18, 2025 | markets.businessinsider.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by AnalystsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objecFebruary 17, 2025 | marketbeat.comInvestingPro Fair Value analysis proves accurate on Spyre Therapeutics callFebruary 10, 2025 | msn.comSpyre Therapeutics Announces Grants of Inducement AwardsFebruary 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREFebruary 4, 2025 | prnewswire.comChina Universal Asset Management Co. Ltd. Acquires New Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)China Universal Asset Management Co. Ltd. bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 12,440 shares of the company's stock, valued at approximately $2February 3, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREJanuary 28, 2025 | prnewswire.comAssenagon Asset Management S.A. Has $527,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Assenagon Asset Management S.A. decreased its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 98.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,652 shares of the comJanuary 26, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by BrokeragesShares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-monJanuary 23, 2025 | marketbeat.comPromising Expansion in Rheumatoid Arthritis Drives Buy Rating for Spyre TherapeuticsJanuary 22, 2025 | markets.businessinsider.com Remove Ads Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.800.62▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼73▲SYRE Articles Average Week Remove Ads Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OGN News Today ACLX News Today RNA News Today RARE News Today RYTM News Today SWTX News Today AKRO News Today CRNX News Today SRRK News Today PTGX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYRE Stock Free SYRE Stock Alerts